Search Results - mirna

3 Results Sort By:
Signatures of Genetic Control in Digestive and Liver Disorders
Our technology describes unique genetic signatures in patients with digestive diseases and liver disorders. Using comprehensive analysis of 735 microRNAs and 19,000 mRNAs, we have identified a unique set of microRNAs and/or mRNAs which predict disease phenotypes in patients with digestive and liver disorders. The identification of such point-of- care...
Published: 10/28/2024   |   Inventor(s): Ralph Peace, Nicolaas Fourie, Sarah Abey, Wendy Henderson
Keywords(s): Acid, Altered, CAXXXX, CXXXXX, Digestive, DISORDERS, Expressions, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Identification, IXXXXX, Listed LPM Vepa as of 4/15/2015, liver, MESSENGER, MICRO, miRNA, PHENOTYPE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Ribonucleic, RNA, Species, THERAPY
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology
TUNABLE RNA INTERFERENCE VIA NUCLEOTIDE MISMATCH DESIGN
TUNABLE RNA INTERFERENCE VIA NUCLEOTIDE MISMATCH DESIGN Researchers at Stanford, the University of Massachusetts and the Chan Zuckerberg Biohub have developed methods to increase or decrease RNA interference target cleavage rates. Harnessing the power of RNA interference (RNAi), the biological process of RNA-guided and sequence-specific gene expression...
Published: 10/26/2024   |   Inventor(s): William Greenleaf, Phillip Zamore, Winston Becker, Benjamin Ober-Reynolds, Karina Jouravleva, Samson Jolly
Keywords(s): Gene Expression, miRNA, Nucleotide, RNAi, siRNA
Category(s): Technology Classifications > Biology
MiRNAs as Novel Therapeutics and Non-invasive Biomarkers for Bone Metastasis
Princeton Docket # 12-2807 Researchers in the Molecular Biology Department at Princeton University have discovered a group of miRNAs as novel therapeutics for bone metastasis. Through a series of in vitro and in vivo experiments, five distinctive miRNAs have been identified as inhibitors of osteoclast differentiation. Further, systemic treatment...
Published: 3/30/2022   |   Inventor(s): Yibin Kang, Brian Ell
Keywords(s): biomarker/diagnostic, Biotechnology/Pharmaceuticals, cancer/oncology, drug discovery, miRNA, therapeutic
Category(s): Biotechnology/Pharmaceuticals, Medical Devices/Diagnostics